The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma.

MLA

Albin, Nicolas, et al. “The Clinical Added Value of the Addition of Anti-CTL-4 to Anti-PD-1 Alone Is Questionable and Clearly Increasing Toxicity Regarding Pivotal Studies in the Treatment of Melanoma and Renal Carcinoma.” Cancer Chemotherapy and Pharmacology, vol. 83, no. 5, May 2019, pp. 1003–05. EBSCOhost, https://doi.org/10.1007/s00280-019-03804-7.

APA

Albin, N., Monard, A., & Lapiere, J. (2019). The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma. Cancer Chemotherapy and Pharmacology, 83(5), 1003–1005. https://doi.org/10.1007/s00280-019-03804-7

Chicago

Albin, Nicolas, Adrien Monard, and Jérémy Lapiere. 2019. “The Clinical Added Value of the Addition of Anti-CTL-4 to Anti-PD-1 Alone Is Questionable and Clearly Increasing Toxicity Regarding Pivotal Studies in the Treatment of Melanoma and Renal Carcinoma.” Cancer Chemotherapy and Pharmacology 83 (5): 1003–5. doi:10.1007/s00280-019-03804-7.